<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02098486</url>
  </required_header>
  <id_info>
    <org_study_id>ERCPMOXIVSCEF</org_study_id>
    <nct_id>NCT02098486</nct_id>
  </id_info>
  <brief_title>Comparisons of Intravenous Ceftriaxone With Intravenous Moxifloxacin in ERCP</brief_title>
  <official_title>Antibiotic Prophylaxis for ERCP: a Comparison of Intravenous Ceftriaxone With Intravenous Moxifloxacin in the Prophylaxis of Cholangitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kangbuk Samsung Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and aims: The use of prophylactic antibiotics before endoscopic retrograde
      cholangiopancreatography (ERCP) is recommended by all major international gastroenterological
      societies, especially in the presence of an obstructed biliary system. Their use is intended
      to decrease or eliminate the incidence of complications following the procedure, namely
      cholangitis, cholecystitis, septicemia, and pancreatitis. However, there were a few reports
      concerning the dosage, duration and adopting antibiotics most suitable for this purpose. The
      aim of this prospective comparative study is to compare the occurrence rate of
      post-procedural complications, such as cholangitis, bacteremia and septicemia between
      intravenous moxifloxacin and ceftriaxone for the prophylactic use in patients with bile duct
      obstruction who will undergo therapeutic ERCP procedure.

      Methods: In this prospective study, a total of 160 patients (calculated by IBM SPSS Sample
      Power, version 3.0) with bile duct obstruction due to variable causes (bile duct stones,
      benign or malignant stricture, etc) will be enrolled and randomly allocated to intravenous
      moxifloxacin and ceftriaxone group, respectively (using simple randomization program).
      Intravenous moxifloxacin (400 mg/day, infused more than 60 min) or ceftriaxone (2 g/day,
      diluted in 40 cc of 5% dextrose water, infused more than 30 min) will be given 90 minutes
      before ERCP procedure, and will be given to a patient for more than 3 days if the patient
      develops symptoms and signs of cholangitis or septicemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cholangitis</measure>
    <time_frame>3 days</time_frame>
    <description>To compare the occurrence rate of cholangitis between the intravenous moxifloxacin and ceftriaxone group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30 day mortality</measure>
    <time_frame>30 days</time_frame>
    <description>To compare the occurrence rate of 30-day mortality between moxifloxacin and ceftriaxone treated group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Cholangitis</condition>
  <arm_group>
    <arm_group_label>Ceftraxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ceftriaxone (2 g/day, diluted in 40 cc of 5% dextrose water, infused more than 30 min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous moxifloxacin (400 mg/day, infused more than 60 min)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftriaxone</intervention_name>
    <arm_group_label>Ceftraxone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with bile duct obstruction due to variable causes (bile duct stones, benign
             or malignant stricture, etc)

        Exclusion Criteria:

          -  pregnancy

          -  hypersensitivity to moxifloxacin and/or ceftriaxone

          -  previous antibiotic exposure or theophyllin derivatives medication within 14 days of
             admission

          -  previous history of epilepsy

          -  previous history of endocarditis of valvular heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Joo Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sungkyunkwan University Kangbuk Samsung Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sungkyunkwan University Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-746</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2014</study_first_submitted>
  <study_first_submitted_qc>March 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2014</study_first_posted>
  <last_update_submitted>February 22, 2016</last_update_submitted>
  <last_update_submitted_qc>February 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kangbuk Samsung Hospital</investigator_affiliation>
    <investigator_full_name>Hong Joo Kim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Bile duct obstruction</keyword>
  <keyword>Cholangitis</keyword>
  <keyword>Moxifloxacin</keyword>
  <keyword>Ceftriaxone</keyword>
  <keyword>Sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

